Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Ascending Doses of Subcutaneous Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

NCT04072237 is registered in ClinicalTrials.gov with Catalyst Biosciences as lead sponsor.

NCT NCT04072237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04072237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Ascending Doses of Subcutaneous Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
Lead sponsor
Catalyst Biosciences
Phase
Phase 1
Overall status
Completed
Start date
September 24, 2019
Completion date
June 17, 2020
Enrollment
11 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a, hemophilia a with inhibitor, hemophilia a without inhibitor, hemophilia b, hemophilia b with inhibitor, hemophilia b without inhibitor